Sparfloxacin worldwide in vitro literature: Isolate data available through 1994
Sparfloxacin is a piperazinyl, cyclopropyl-fluoroquinolone with broad-spectrum antibacterial activity. Compared to other quinolones, sparfloxacin displays improved activity against a variety of pathogens including Staphylococcus, Streptococcus, Enterococcus, Chlamydia, Mycoplasma, Ureaplasma, and My...
Gespeichert in:
| Veröffentlicht in: | Diagnostic microbiology and infectious disease 1996-06, Vol.25 (2), p.53-64 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 64 |
|---|---|
| container_issue | 2 |
| container_start_page | 53 |
| container_title | Diagnostic microbiology and infectious disease |
| container_volume | 25 |
| creator | Cohen, Michael A. Yoder, Steven L. Talbot, George H. |
| description | Sparfloxacin is a piperazinyl, cyclopropyl-fluoroquinolone with broad-spectrum antibacterial activity. Compared to other quinolones, sparfloxacin displays improved activity against a variety of pathogens including
Staphylococcus, Streptococcus, Enterococcus, Chlamydia, Mycoplasma, Ureaplasma, and
Mycobacteria species. Other susceptible organism groups include
Haemophilus, Legionella, Moraxella, Neisseria, Aeromonas, Acinetobacter, Bordetella, Brucella, Campylobacter, Gardnerella, and
Helicobacter species. Most Enterobacteriaceae are also susceptible, whereas most isolates of
Pseudomonas aeruginosa are not. Sparfloxacin is bactericidal. Activity is generally stable to variations of inoculum, pH, and cation concentration, and it is unchanged in the presence of 5% sodium cholate or 70% human serum. Susceptibility to the drug is diminished in urine. Cross-resistance, although incomplete, has been documented with other quinolones, but not with other antimicrobic classes. |
| doi_str_mv | 10.1016/S0732-8893(96)00121-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78467255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0732889396001216</els_id><sourcerecordid>78467255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-1cefb455940ff217199e335c1aba1159f29711165f3c0787b110f81319be477e3</originalsourceid><addsrcrecordid>eNqFkE1r3DAQhkVJSbZJf0LAhxDag1uNZVtSLqGEfgQCOaQ5i7E8alS0q40kb9p_X2922WtPwzDPOzM8jJ0D_wQc-s8PXIqmVkqLD7r_yDk0UPdv2AKU1DXnkh-xxQE5Ye9y_r2FdMuP2bFSqlGaL9j9wxqTC_EPWr-qXmIK44sfqZqbjS8pVsEXSlimRFfVbY4BC1UjFqxwgz7gEKgqTylOv54q0Lo9Y28dhkzv9_WUPX77-vPmR313__325stdbYXSpQZLbmi7bv7GuQbkHCUhOgs4IECnXaMlAPSdE5ZLJQcA7hQI0AO1UpI4ZZe7vesUnyfKxSx9thQCrihO2UjV9rLpuhnsdqBNMedEzqyTX2L6a4CbrUjzKtJsLRndm1eRpp9z5_sD07Ck8ZDam5vnF_s5ZovBJVxZnw-YaEDzRs3Y9Q6jWcbGUzLZelpZGn0iW8wY_X8e-Qchw44T</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78467255</pqid></control><display><type>article</type><title>Sparfloxacin worldwide in vitro literature: Isolate data available through 1994</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cohen, Michael A. ; Yoder, Steven L. ; Talbot, George H.</creator><creatorcontrib>Cohen, Michael A. ; Yoder, Steven L. ; Talbot, George H.</creatorcontrib><description>Sparfloxacin is a piperazinyl, cyclopropyl-fluoroquinolone with broad-spectrum antibacterial activity. Compared to other quinolones, sparfloxacin displays improved activity against a variety of pathogens including
Staphylococcus, Streptococcus, Enterococcus, Chlamydia, Mycoplasma, Ureaplasma, and
Mycobacteria species. Other susceptible organism groups include
Haemophilus, Legionella, Moraxella, Neisseria, Aeromonas, Acinetobacter, Bordetella, Brucella, Campylobacter, Gardnerella, and
Helicobacter species. Most Enterobacteriaceae are also susceptible, whereas most isolates of
Pseudomonas aeruginosa are not. Sparfloxacin is bactericidal. Activity is generally stable to variations of inoculum, pH, and cation concentration, and it is unchanged in the presence of 5% sodium cholate or 70% human serum. Susceptibility to the drug is diminished in urine. Cross-resistance, although incomplete, has been documented with other quinolones, but not with other antimicrobic classes.</description><identifier>ISSN: 0732-8893</identifier><identifier>EISSN: 1879-0070</identifier><identifier>DOI: 10.1016/S0732-8893(96)00121-6</identifier><identifier>PMID: 8882890</identifier><identifier>CODEN: DMIDDZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Anti-Infective Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Fluoroquinolones ; Medical sciences ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Quinolones - chemistry ; Quinolones - pharmacology</subject><ispartof>Diagnostic microbiology and infectious disease, 1996-06, Vol.25 (2), p.53-64</ispartof><rights>1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-1cefb455940ff217199e335c1aba1159f29711165f3c0787b110f81319be477e3</citedby><cites>FETCH-LOGICAL-c389t-1cefb455940ff217199e335c1aba1159f29711165f3c0787b110f81319be477e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0732889396001216$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3219028$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8882890$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Michael A.</creatorcontrib><creatorcontrib>Yoder, Steven L.</creatorcontrib><creatorcontrib>Talbot, George H.</creatorcontrib><title>Sparfloxacin worldwide in vitro literature: Isolate data available through 1994</title><title>Diagnostic microbiology and infectious disease</title><addtitle>Diagn Microbiol Infect Dis</addtitle><description>Sparfloxacin is a piperazinyl, cyclopropyl-fluoroquinolone with broad-spectrum antibacterial activity. Compared to other quinolones, sparfloxacin displays improved activity against a variety of pathogens including
Staphylococcus, Streptococcus, Enterococcus, Chlamydia, Mycoplasma, Ureaplasma, and
Mycobacteria species. Other susceptible organism groups include
Haemophilus, Legionella, Moraxella, Neisseria, Aeromonas, Acinetobacter, Bordetella, Brucella, Campylobacter, Gardnerella, and
Helicobacter species. Most Enterobacteriaceae are also susceptible, whereas most isolates of
Pseudomonas aeruginosa are not. Sparfloxacin is bactericidal. Activity is generally stable to variations of inoculum, pH, and cation concentration, and it is unchanged in the presence of 5% sodium cholate or 70% human serum. Susceptibility to the drug is diminished in urine. Cross-resistance, although incomplete, has been documented with other quinolones, but not with other antimicrobic classes.</description><subject>Anti-Infective Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Fluoroquinolones</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinolones - chemistry</subject><subject>Quinolones - pharmacology</subject><issn>0732-8893</issn><issn>1879-0070</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1r3DAQhkVJSbZJf0LAhxDag1uNZVtSLqGEfgQCOaQ5i7E8alS0q40kb9p_X2922WtPwzDPOzM8jJ0D_wQc-s8PXIqmVkqLD7r_yDk0UPdv2AKU1DXnkh-xxQE5Ye9y_r2FdMuP2bFSqlGaL9j9wxqTC_EPWr-qXmIK44sfqZqbjS8pVsEXSlimRFfVbY4BC1UjFqxwgz7gEKgqTylOv54q0Lo9Y28dhkzv9_WUPX77-vPmR313__325stdbYXSpQZLbmi7bv7GuQbkHCUhOgs4IECnXaMlAPSdE5ZLJQcA7hQI0AO1UpI4ZZe7vesUnyfKxSx9thQCrihO2UjV9rLpuhnsdqBNMedEzqyTX2L6a4CbrUjzKtJsLRndm1eRpp9z5_sD07Ck8ZDam5vnF_s5ZovBJVxZnw-YaEDzRs3Y9Q6jWcbGUzLZelpZGn0iW8wY_X8e-Qchw44T</recordid><startdate>19960601</startdate><enddate>19960601</enddate><creator>Cohen, Michael A.</creator><creator>Yoder, Steven L.</creator><creator>Talbot, George H.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960601</creationdate><title>Sparfloxacin worldwide in vitro literature: Isolate data available through 1994</title><author>Cohen, Michael A. ; Yoder, Steven L. ; Talbot, George H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-1cefb455940ff217199e335c1aba1159f29711165f3c0787b110f81319be477e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Anti-Infective Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Fluoroquinolones</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinolones - chemistry</topic><topic>Quinolones - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Michael A.</creatorcontrib><creatorcontrib>Yoder, Steven L.</creatorcontrib><creatorcontrib>Talbot, George H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diagnostic microbiology and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Michael A.</au><au>Yoder, Steven L.</au><au>Talbot, George H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sparfloxacin worldwide in vitro literature: Isolate data available through 1994</atitle><jtitle>Diagnostic microbiology and infectious disease</jtitle><addtitle>Diagn Microbiol Infect Dis</addtitle><date>1996-06-01</date><risdate>1996</risdate><volume>25</volume><issue>2</issue><spage>53</spage><epage>64</epage><pages>53-64</pages><issn>0732-8893</issn><eissn>1879-0070</eissn><coden>DMIDDZ</coden><abstract>Sparfloxacin is a piperazinyl, cyclopropyl-fluoroquinolone with broad-spectrum antibacterial activity. Compared to other quinolones, sparfloxacin displays improved activity against a variety of pathogens including
Staphylococcus, Streptococcus, Enterococcus, Chlamydia, Mycoplasma, Ureaplasma, and
Mycobacteria species. Other susceptible organism groups include
Haemophilus, Legionella, Moraxella, Neisseria, Aeromonas, Acinetobacter, Bordetella, Brucella, Campylobacter, Gardnerella, and
Helicobacter species. Most Enterobacteriaceae are also susceptible, whereas most isolates of
Pseudomonas aeruginosa are not. Sparfloxacin is bactericidal. Activity is generally stable to variations of inoculum, pH, and cation concentration, and it is unchanged in the presence of 5% sodium cholate or 70% human serum. Susceptibility to the drug is diminished in urine. Cross-resistance, although incomplete, has been documented with other quinolones, but not with other antimicrobic classes.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>8882890</pmid><doi>10.1016/S0732-8893(96)00121-6</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-8893 |
| ispartof | Diagnostic microbiology and infectious disease, 1996-06, Vol.25 (2), p.53-64 |
| issn | 0732-8893 1879-0070 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78467255 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anti-Infective Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Fluoroquinolones Medical sciences Microbial Sensitivity Tests Pharmacology. Drug treatments Quinolones - chemistry Quinolones - pharmacology |
| title | Sparfloxacin worldwide in vitro literature: Isolate data available through 1994 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A38%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sparfloxacin%20worldwide%20in%20vitro%20literature:%20Isolate%20data%20available%20through%201994&rft.jtitle=Diagnostic%20microbiology%20and%20infectious%20disease&rft.au=Cohen,%20Michael%20A.&rft.date=1996-06-01&rft.volume=25&rft.issue=2&rft.spage=53&rft.epage=64&rft.pages=53-64&rft.issn=0732-8893&rft.eissn=1879-0070&rft.coden=DMIDDZ&rft_id=info:doi/10.1016/S0732-8893(96)00121-6&rft_dat=%3Cproquest_cross%3E78467255%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78467255&rft_id=info:pmid/8882890&rft_els_id=S0732889396001216&rfr_iscdi=true |